YB-1113 / YB Life Science, Bright Cell - LARVOL DELTA

Safety and Efficacy of YB-1113 in Treatment of POI (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Bright Cell, Inc. | Trial completion date: Aug 2028 ➔ Apr 2028 | Trial primary completion date: Jul 2027 ➔ Jan 2028

Trial completion date • Trial primary completion date • Women's Health

Safety and Efficacy of YB-1113 in Treatment of POI (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Bright Cell, Inc. | Trial completion date: Aug 2027 ➔ Aug 2028 | Trial primary completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Women's Health

Safety and Efficacy of YB-1113 in Treatment of POI (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Bright Cell, Inc. | Trial completion date: Aug 2025 ➔ Aug 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Women's Health

Safety and Efficacy of YB-1113 in Treatment of POI (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: YB Life Science, LLC | Phase classification: P1/2 ➔ P1

Phase classification • Women's Health

Safety and Efficacy of YB-1113 in Treatment of POI (clinicaltrials.gov) - P1/2 | N=6 | Not yet recruiting | Sponsor: YB Life Science, LLC

New P1/2 trial • Women's Health